Evidence map›Paper›PMID 31077056›Full record

ArticleCEN case reports2019

Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.

Hirotaka Saito, Kenichi Tanaka, Momoko Fujiwara, Tsuyoshi Iwasaki, Tokutaro Numata, Akira Oda, Makoto Kanno, Mizuko Tanaka, Masaaki Eiro, Mamoru Satoh and 1 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in CEN case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hirotaka SaitoDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan.
Kenichi TanakaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan. kennichi@fmu.ac.jp.ORCID 0000-0003-4655-9355
Momoko FujiwaraDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan.
Tsuyoshi IwasakiDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan.
Tokutaro NumataDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan.
Akira OdaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan.
Makoto KannoDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan.
Mizuko TanakaDepartment of Basic Pathology, Fukushima Medical University, Fukushima, Japan.
Masaaki EiroDepartment of Nephrology, Ohta Nishinouchi Hospital, Koriyama, Japan.
Mamoru SatohDepartment of Nephrology, Ohta Nishinouchi Hospital, Koriyama, Japan.
Junichiro James KazamaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Japan.
Fukushima Medical University · JPOhta Nishinouchi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman's disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.

Indexed as

Abdominal PainAnti-Inflammatory AgentsCastleman DiseaseCyclosporineFemaleFeverGlomerulonephritis, MembranoproliferativeHumansImmunosuppressive AgentsKidneyKidney GlomerulusMethylprednisoloneMiddle AgedThrombocytopeniaTreatment OutcomeVascular Endothelial Growth Factor AAnti-Inflammatory AgentsCyclosporineImmunosuppressive AgentsMethylprednisoloneVascular Endothelial Growth Factor AKidney biopsyTAFRO syndromeThrombotic microangiopathyVascular endothelial growth factor

Identifiers

PMID31077056
PMCPMC6820645
OpenAlexW2943940432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.